Breast cancer remains the second leading cause of cancer death in women in the US and it is estimated that 40,460 American women will die of the disease in 2007.
Moreover, recurrence has a significant impact on breast cancer mortality. Indeed, distant metastasis-the most common form of recurrence in the majority of cases [2] [3] [4] -represents the main cause of death in women with breast cancer. 5 In recent decades improvements in early detection and the recognized benefits of adjuvant systemic therapy in reducing risk of distant relapse has contributed to a steady decline in breast cancer mortality, 6, 7 but despite these advances distant metastasis remains a challenge. Improvements in screening and imaging techniques have helped in the early detection of breast cancer and this, in turn, has resulted in a greater number of patients presenting with early-stage breast cancer. In patients with early disease, a multimodal approach to treatment is essential for improving survival. Breast cancer recurrence-particularly distant recurrence-in women with earlystage disease is associated with increased mortality. 8 Treatments that can address the risk of breast cancer recurrence, especially distant metastases, have the potential to remain disease-free and improve overall survival in women with early-stage breast cancer. Adjuvant systemic therapy has demonstrated its benefits in reducing the risk of occult micrometastatic infiltration and is now recommended clinical practice for patients with nodepositive and high-risk, node-negative breast cancer. 9 The challenges associated with distant recurrence in early-stage breast cancer are discussed in this review, with a focus on adjuvant endocrine therapy.
Early Breast Cancer and Distant Metastases
Widespread screening coupled with advances in imaging technologies has resulted in earlier detection of breast cancer. Consequently, more than half of the women currently presenting with breast cancer in the US have an early-stage form of the disease. 10 Early-stage invasive breast cancer is defined as breast cancer that has not spread beyond the breast or the axillary lymph nodes, and includes ductal carcinoma in situ, stage I, stage IIA, stage IIB, and stage IIIA breast cancers (see Table 1 ). 22 In early breast cancer, nodal status is a significant prognostic indicator and the risk of distant metastasis has been directly related to the number of axillary nodes involved. 23 However, even patients with nodenegative disease are at risk of distant relapse. and those who had more than four positive nodes were at the greatest risk of relapse. Between years two and five the risk of recurrence slowly declined.
From years five to 12, the mean hazard of recurrence remained constant at over 4% per year. Of note, patients with hormone receptor-negative, highly proliferate disease had a higher risk of relapse in the first five years after diagnosis, then their relapse rate sharply declined. Moreover, from years five to 12, the risk was significantly less than in OR-positive disease. 25 The Early Breast
Cancer Trialists' Collaborative Group (EBCTCG) identified that women with hormone receptor-positive breast cancer have approximately 50% of their initial recurrence risk after year five. Furthermore, the risk of recurrences, particularly distance metastasis, remained as late as 15 years after diagnosis.
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Adjuvant Chemotherapy
There have been numerous studies using single-agent and polychemotherapy adjuvant regimens in early-stage breast cancer. EBCTCG meta-analyses of many of these trials clearly demonstrate that adjuvant chemotherapy can reduce the risk of recurrence in women with early-stage breast cancer. 26, 27 Before the introduction of the taxanes-a group of drugs-the two most The study also demonstrated a 26% reduction in the relative risk of death in the CMF arm. 28, 29 The armamentarium of chemotherapeutic agents available for the treatment of breast cancer has expanded greatly over the past few decades, including the use of anthracyclins and taxanes. An overview of some of the advances was recently published. 2% per annum in node-negative patients; and 4% per annum in node-positive patients during the study period. 23 However, the benefits conferred by tamoxifen were not extended beyond five years and some studies have even shown detrimental effects. 2 Furthermore, the EBCTCG meta-analysis reported that more than half of breast cancer recurrences and deaths occur after the completion of tamoxifen therapy, which suggests that tamoxifen may be less effective at preventing distant relapses than loco-regional recurrences. and an overview of advances in OA in this setting was recently published. 34 An EBCTCG meta-analysis of the impact of OA on breast cancer recurrence revealed that at 15-year follow-up, pre-menopausal women treated with OA had statistically significantly higher relapse-free survival and OS rates (45 versus 39% and 52.4 versus 46.1%, respectively) compared with women in the control group. Interestingly, trials of OA plus chemotherapy compared with chemotherapy alone have shown no additional benefit. 35 Recently the role of Stage 0  Tis  N0  M0  Stage I  T1*  N0  M0  Stage IIA  T0  N1  M0  T1*  N1  M0  T2  N0  M0  Stage IIB  T2  N1  M0  T3  N0  M0  Stage IIIA  T0  N2  M0  T1*  N2  M0  T2  N2  M0  T3  N1  M0  T3 N2 M0 who were randomized to continue tamoxifen or to switch to anastrozole after completing two years of adjuvant tamoxifen therapy. It revealed that women switching to anastrozole showed a significant improvement in event-free survival and a significant decrease in risk of metastasis (40 and 39%, respectively) compared with those continuing tamoxifen, at a median follow-up of 28 months. However, OS was not significantly different between the groups. 38 Letrozole has also been studied in large phase III randomized, controlled trials in both the adjuvant and sequential adjuvant setting. In the Breast International Group 1-98 (BIG 1-98) trial, 8,028 post-menopausal women with endocrine-responsive breast cancer compared the effectiveness of tamoxifen or letrozole alone (five years), tamoxifen for two years followed by letrozole for three years, and letrozole for two years followed by tamoxifen three years. 39 The results from the primary core analysis of the trial data, which analyzed all events in the monotherapy, and the sequential arms up to the time of treatment switch (two years of therapy) with a median follow-up of 25.8 months revealed that letrozole monotherapy resulted in a significantly lower risk for recurrence with five-year DFS rate estimates of 84% compared with 81.4%
for the tamoxifen group. Importantly, letrozole resulted in significantly fewer 
Recurrences
Unfortunately, many women with hormone receptor-positive early breast cancer will experience a recurrence, and this can occur at any stage of disease, observation time, and after any treatment modality. An EBCTCG meta-analysis showed that the risk of recurrence risk was greatest in the first few years following initial diagnosis of early breast cancer for those patients not receiving adjuvant endocrine therapy. 43 Moreover, the risk of recurrence remains up to 15 years post-diagnosis.
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Pattern-Local versus Distant
The most common recurrence event in women with breast cancer is distant metastasis. This is due, in part, to improvements in surgical techniques and the greater adoption of radiotherapy following breast conservation surgery, which has resulted in a reduction in local recurrence risks. 44 Advances in imaging technology have also alleviated the problem of missing extensive or multifocal sites of cancer in the breast at the time of surgery. 45 A retrospective cohort study showed that median time to all-cause mortality is significantly longer in women with loco-regional recurrence than in those with distant metastasis (6.4 versus 3.4 years, respectively). 46 Moreover, 10-year survival in women with local recurrence was 56% compared with 9% in those with distant recurrence.
Strategies to Improve Outcomes
Starting tamoxifen therapy with the intention of switching to an AI after 2.5 or five years could potentially forfeit the early benefits associated with AIs over tamoxifen. 48 Moreover, it must be noted that several studies have indicated that anastrozole greatly reduces the risk of early local recurrence, but not in the reduction of distant metastasis, which is the most common early relapse event and a surrogate for OS. 49, 50 In contrast, recent data from the BIG 1-98
show that letrozole had a large impact on reducing early distant recurrences (30% fewer distant recurrences). 51 Furthermore, if, theoretically, an AI might partially inhibit the activation of dormant metastasis by the act of surgery, then an AI should be started at the time of (or even prior to) surgery to maximize this benefit.
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Conclusions
Recurrences from breast cancer after successful therapy still cause major morbidity and mortality in spite of the use of adjuvant treatment.
More recently, it has become clear that replacing tamoxifen in initial adjuvant endocrine therapy with an AI can avoid a number of early recurrences in post-menopausal women. There is also increasing evidence that AIs can reduce the risk of distant recurrences. This is particularly important because these more often lead to death of the patient. With the early use of AIs, we are improving outcomes and, potentially, saving more lives. ■
